PT  - JOURNAL ARTICLE
AU  - Limonta-Fernández, Miladys
AU  - Chinea-Santiago, Glay
AU  - Martín-Dunn, Alejandro Miguel
AU  - Gonzalez-Roche, Diamile
AU  - Bequet-Romero, Monica
AU  - Marquez-Perera, Gabriel
AU  - González-Moya, Isabel
AU  - Canaan-Haden-Ayala, Camila
AU  - Cabrales-Rico, Ania
AU  - Espinosa-Rodríguez, Luis Ariel
AU  - Ramos-Gómez, Yassel
AU  - Andujar-Martínez, Ivan
AU  - González-López, Luis Javier
AU  - de la Iglesia, Mariela Perez
AU  - Zamora-Sanchez, Jesus
AU  - Cruz-Sui, Otto
AU  - Lemos-Pérez, Gilda
AU  - Cabrera-Herrera, Gleysin
AU  - Valdes-Hernández, Jorge
AU  - Martinez-Diaz, Eduardo
AU  - Pimentel-Vazquez, Eulogio
AU  - Ayala-Avila, Marta
AU  - Guillén-Nieto, Gerardo
TI  - The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigen
AID  - 10.1101/2021.06.29.21259605
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.29.21259605
4099  - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259605.short
4100  - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259605.full
AB  - The effort to develop vaccines based on economically accessible technological platforms available by developing countries vaccine manufacturers is essential to extend the immunization to the whole world population and to achieve the desired herd immunity, necessary to end the COVID-19 pandemic. Here we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed in yeast Pichia pastoris. The RBD was modified with addition of flexible N- and C-terminal amino acid extensions aimed to modulate the protein/protein interactions and facilitate protein purification. Fermentation with yeast extract culture medium yielded 30–40 mg/L. After purification by immobilized metal ion affinity chromatography and hydrophobic interaction chromatography, the RBD protein was characterized by mass-spectrometry, circular dichroism, and binding affinity to angiotensin-converting enzyme 2 (ACE2) receptor. The recombinant protein shows high antigenicity with convalescent human sera and also with sera from individuals vaccinated with the Pfizer-BioNTech mRNA or Sputnik V adenoviral-based vaccines. The RBD protein stimulates IFNγ, IL-2, IL-6, IL-4, and TNFα in mice secreting splenocytes from PBMC and lung CD3+ enriched cells. Immunogenicity studies with 50 µg of the recombinant RBD formulated with alum, induce high levels of binding antibodies in mice and non-human primates, assessed by ELISA plates covered with RBD protein expressed in HEK293T cells. The mouse sera inhibited the RBD binding to ACE2 receptor in an in-vitro test and show neutralization of SARS-CoV-2 infection of Vero E6 cells. These data suggest that the RBD recombinant protein expressed in yeast P. pastoris is suitable as a vaccine candidate against COVID-19.HighlightsThe RBD protein (C-RBD-H6 PP) is expressed with high purity in P. pastoris.Physico-chemical characterization confirms the right folding of the protein.The recombinant protein shows high antigenicity with sera from convalescents.The sera from animals inhibit the RBD-ACE2 binding and neutralize the virus.The C-RBD-H6 protein stimulates IFNγ, IL-2, IL-6, IL-4, and TNFα in mice.Competing Interest StatementMLF, MBR, AMMD, DGR, ACR, GCS, GMP, EPV, MAA and GGN are co-authors of the Center for Genetic Engineering and Biotechnology patent application comprising the C-RBD-H6 PP protein as a vaccine antigen against SASR-CoV-2. All authors approved integrally the final article. Funding StatementThis work was supported with funds from the BioCubaFarma, the Center for Genetic Engineering and Biotechnology, and by the Grant of the National Science and Technology Program - Biotechnology, Pharmaceutical Industry and Medical Technologies, of the Ministry of Science and Technology, project code PN385LH007-048. The Civilian Defense Scientific Research Center supported the microneutralization assays.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Center for Genetic Engineering and Biotechnology Institutional Ethical Committee approved the Informed Consent requested to human volunteers for the serum samples used. The animal studies Ethical Committee on Animal Experimentation of the Center for Genetic Engineering and Biotechnology (CIGB, Havana, Cuba) and the Center for Production of Laboratory Animals (CENPALAB, Bejucal, Cuba)approved the animal experiments.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are included in the manuscript or can be accessible upon request.RBDReceptor-binding domainCOVID-19coronavirus disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2ACE2angiotensin-converting enzyme 2PBMCperipheral blood mononuclear cellsIL-2Interleukin 2IL-4Interleukin 4IL-6Interleukin 6TNFαtumor necrosis factor-alphaIFNγinterferon gammaNHPnon-human primatesCHOChinese hamster ovary cellsBHK21baby hamster kidney cellsHEK293Thuman embryonic kidney cellsIMACimmobilized metal ion affinity chromatographyRPreversed-phase chromatographyCDcircular dichroismODoptical densityVNTviral neutralization titer